Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRONASDAQ:FIXXNASDAQ:MRUSNASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$45.32-1.5%$41.03$17.86▼$58.40$3.67B-0.12964,102 shs999,121 shsFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsMRUSMerus$50.01-1.6%$42.99$33.19▼$61.28$3.46B0.94731,600 shs1.39 million shsSRPTSarepta Therapeutics$37.23-2.9%$52.32$34.10▼$173.25$3.66B0.851.80 million shs3.27 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics-1.48%-6.27%+7.47%-5.09%+132.41%FIXXHomology Medicines0.00%0.00%0.00%0.00%0.00%MRUSMerus-1.56%+15.74%+10.45%+8.20%-8.86%SRPTSarepta Therapeutics-2.92%-7.04%-39.47%-63.88%-67.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics4.0799 of 5 stars3.53.00.04.73.11.70.0FIXXHomology MedicinesN/AN/AN/AN/AN/AN/AN/AN/AMRUSMerus2.81 of 5 stars4.62.00.00.02.61.70.0SRPTSarepta Therapeutics4.7388 of 5 stars4.42.00.04.22.62.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$82.5082.04% UpsideFIXXHomology Medicines 0.00N/AN/AN/AMRUSMerus 3.13Buy$86.0071.97% UpsideSRPTSarepta Therapeutics 2.83Moderate Buy$122.61229.33% UpsideCurrent Analyst Ratings BreakdownLatest FIXX, MRUS, SRPT, and AKRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/22/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$40.00 ➝ $40.005/20/2025SRPTSarepta TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$169.00 ➝ $84.005/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.005/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.005/8/2025SRPTSarepta TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy$188.00 ➝ $85.005/8/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$115.00 ➝ $100.005/8/2025SRPTSarepta TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline$50.005/7/2025SRPTSarepta TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$87.00 ➝ $58.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$9.61 per shareN/AFIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00MRUSMerus$54.73M63.24N/AN/A$6.17 per share8.11SRPTSarepta Therapeutics$2.23B1.64N/AN/A$9.19 per share4.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$151.76M-$1.95N/AN/AN/AN/A-32.46%-29.83%8/8/2025 (Estimated)FIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/AMRUSMerus-$154.94M-$4.08N/AN/AN/A-680.61%-38.89%-31.16%7/30/2025 (Estimated)SRPTSarepta Therapeutics-$535.98M-$2.6929.783.40N/A7.43%11.00%3.35%8/6/2025 (Estimated)Latest FIXX, MRUS, SRPT, and AKRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million2/28/2025Q4 2024AKROAkero Therapeutics-$0.98-$0.99-$0.01-$0.99N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AFIXXHomology MedicinesN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0517.2517.25FIXXHomology MedicinesN/A7.257.25MRUSMerusN/A8.328.32SRPTSarepta Therapeutics0.933.843.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AFIXXHomology Medicines31.32%MRUSMerus96.14%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.94%FIXXHomology Medicines16.10%MRUSMerus4.57%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.72 million64.26 millionOptionableFIXXHomology Medicines758.13 million48.77 millionOptionableMRUSMerus3769.21 million65.34 millionOptionableSRPTSarepta Therapeutics84098.28 million88.17 millionOptionableFIXX, MRUS, SRPT, and AKRO HeadlinesRecent News About These CompaniesD. E. Shaw & Co. Inc. Sells 11,389,239 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 28 at 3:25 AM | marketbeat.comWas Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?May 27 at 10:37 AM | insidermonkey.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $36.39 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 27 at 4:40 AM | marketbeat.comTwo Sigma Investments LP Has $9.13 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 27 at 4:27 AM | marketbeat.com46,986 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Purchased by Woodline Partners LPMay 26 at 4:37 AM | marketbeat.comHC Wainwright Reaffirms "Neutral" Rating for Sarepta Therapeutics (NASDAQ:SRPT)May 25, 2025 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Receives "Neutral" Rating from HC WainwrightMay 24, 2025 | marketbeat.comSarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | BenzingaMay 23, 2025 | benzinga.comSarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | BenzingaMay 23, 2025 | benzinga.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up - Still a Buy?May 23, 2025 | marketbeat.comJPMorgan Chase & Co. Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $84.00May 23, 2025 | americanbankingnews.comFDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne studyMay 22, 2025 | biopharmadive.comSarepta Can Start Dosing Elevidys Trial, UK Regulators SayMay 22, 2025 | precisionmedicineonline.comSarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study ContinueMay 21, 2025 | marketwatch.comSarepta, Roche get U.K. feedback to lift clinical hold on Elevidys' Duchenne trialMay 21, 2025 | msn.comSarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in DuchenneMay 21, 2025 | finance.yahoo.comSarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular DystrophyMay 21, 2025 | businesswire.comVestal Point Capital LP Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 21, 2025 | marketbeat.comTriglav Skladi D.O.O. Invests $1.34 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 21, 2025 | marketbeat.comNuveen Asset Management LLC Increases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 21, 2025 | marketbeat.comSarepta Shares Higher After J.P. Morgan NoteMay 20, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFIXX, MRUS, SRPT, and AKRO Company DescriptionsAkero Therapeutics NASDAQ:AKRO$45.32 -0.68 (-1.48%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$45.78 +0.45 (+1.00%) As of 05/28/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Homology Medicines NASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Merus NASDAQ:MRUS$50.01 -0.79 (-1.56%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$50.36 +0.35 (+0.70%) As of 05/28/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Sarepta Therapeutics NASDAQ:SRPT$37.23 -1.12 (-2.92%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$37.70 +0.47 (+1.26%) As of 05/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
